These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 29909520)

  • 21. Rapid Self-Assembly of Polymer Nanoparticles for Synergistic Codelivery of Paclitaxel and Lapatinib via Flash NanoPrecipitation.
    Levit SL; Yang H; Tang C
    Nanomaterials (Basel); 2020 Mar; 10(3):. PubMed ID: 32244904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
    Hou W; Qin X; Zhu X; Fei M; Liu P; Liu L; Moon H; Zhang P; Greshock J; Bachman KE; Ye BC; Wang H; Zang CY
    Oncol Rep; 2013 Aug; 30(2):707-14. PubMed ID: 23708506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
    Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
    Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma.
    Kondo N; Tsukuda M; Ishiguro Y; Kimura M; Fujita K; Sakakibara A; Takahashi H; Toth G; Matsuda H
    Oncol Rep; 2010 Apr; 23(4):957-63. PubMed ID: 20204279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma.
    Hassan MS; Williams F; Awasthi N; Schwarz MA; Schwarz RE; Li J; von Holzen U
    Sci Rep; 2019 Nov; 9(1):17608. PubMed ID: 31772236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.
    Guo XF; Zhu XF; Zhong GS; Deng BG
    Dis Esophagus; 2013 Jul; 26(5):487-95. PubMed ID: 22458639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer.
    Guo XF; Li SS; Zhu XF; Dou QH; Liu D
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):383-394. PubMed ID: 29909520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic effects of flavonoids and paclitaxel in cancer treatment: a systematic review.
    Asnaashari S; Amjad E; Sokouti B
    Cancer Cell Int; 2023 Sep; 23(1):211. PubMed ID: 37743502
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 31.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.